Tilarginine
Tilarginine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target nitric oxide synthase, inducible, nitric oxide synthase 3, and nitric oxide synthase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
67 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | 1 | — | 1 | 4 | 9 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | — | — | 1 | 2 | 6 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | 1 | 1 | 3 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | 1 | — | 1 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | 2 | 1 | — | — | 2 |
| Shock | D012769 | — | R57.1 | — | — | 1 | — | — | 1 |
| Cardiogenic shock | D012770 | — | R57.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 5 | — | — | 1 | 7 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 5 | — | — | 1 | 6 |
| Nephritis | D009393 | — | N05 | — | 5 | — | — | — | 5 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 2 | — | — | — | 4 |
| Regional blood flow | D012039 | — | — | 1 | 3 | — | — | — | 4 |
| Ocular physiological phenomena | D009799 | — | — | 1 | 3 | — | — | — | 4 |
| Polycystic kidney diseases | D007690 | — | Q61.3 | 1 | 1 | — | — | — | 2 |
| Autosomal dominant polycystic kidney | D016891 | EFO_1001496 | Q61.2 | 1 | 1 | — | — | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | — | 2 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | — | — | — | 3 | 7 |
| Heart failure | D006333 | EFO_0003144 | I50 | 2 | — | — | — | — | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | — | — | — | 1 | 2 |
| Syndrome | D013577 | — | — | 2 | — | — | — | — | 2 |
| Hypoxia | D000860 | — | R09.02 | 1 | — | — | — | 1 | 2 |
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | 2 | — | — | — | — | 2 |
| Tachycardia | D013610 | — | R00.0 | 2 | — | — | — | — | 2 |
| Essential hypertension | D000075222 | — | I10 | 1 | — | — | — | 1 | 2 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 2 | — | — | — | — | 2 |
| Fibrosis | D005355 | — | — | 2 | — | — | — | — | 2 |
Show 27 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperemia | D006940 | EFO_0003822 | H34.82 | — | — | — | — | 2 | 2 |
| Glomerular filtration rate | D005919 | EFO_0005208 | — | — | — | — | — | 1 | 1 |
| Renal circulation | D012079 | — | — | — | — | — | — | 1 | 1 |
| Renal plasma flow | D017595 | — | — | — | — | — | — | 1 | 1 |
| Blood pressure | D001794 | EFO_0004325 | — | — | — | — | — | 1 | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | — | — | — | 1 | 1 |
| Cold temperature | D003080 | — | — | — | — | — | — | 1 | 1 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tilarginine |
| INN | tilarginine |
| Description | N-Methylarginine is an inhibitor of nitric oxide synthase. Chemically, it is a methyl derivative of the amino acid arginine. It is used as a biochemical tool in the study of physiological role of nitric oxide.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=N)NCCC[C@H](N)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 17035-90-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL256147 |
| ChEBI ID | 28229 |
| PubChem CID | 4366 |
| DrugBank | — |
| UNII ID | 27JT06E6GR (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NOS2
NOS2
NOS3
NOS3
NOS1
NOS1
Organism
Homo sapiens
Gene name
NOS2
Gene synonyms
NOS2A
NCBI Gene ID
Protein name
nitric oxide synthase, inducible
Protein synonyms
HEP-NOS, Hepatocyte NOS, Inducible NO synthase, Inducible NOS, iNOS, nitric oxide synthase 2, inducible, nitric oxide synthase 2A (inducible, hepatocytes), nitric oxide synthase, macrophage, NOS type II, NOS, type II, Peptidyl-cysteine S-nitrosylase NOS2
Uniprot ID
Mouse ortholog
Nos2 (18126)
nitric oxide synthase, inducible (Q8R410)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 345 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use